What Is a Research Peptide? The Pipeline from Lab to Clinic

The term "research peptide" appears throughout scientific literature, but its meaning is often misunderstood. This post explains what research peptides are, how they progress through the clinical pipeline, and what the different stages of evidence actually mean.

What Is a Peptide?

A peptide is a short chain of amino acids — the same building blocks as proteins, but smaller. Most peptides are between 2 and 50 amino acids long. Many are naturally occurring: insulin is a peptide, glucagon is a peptide, growth hormone-releasing hormone is a peptide. Others are synthetic analogues — chemically modified versions designed to improve stability, potency, or receptor selectivity.

What Makes a Peptide a "Research Peptide"?

A research peptide is a compound that:

1. Has a defined chemical structure and mechanism of action
2. Has been studied in controlled laboratory or clinical settings
3. Has not yet been approved by a regulatory body (such as the FDA or EMA) for a specific therapeutic use — or has been approved for one use but is being researched for others

The label reflects regulatory status, not scientific legitimacy. Many research peptides have extensive peer-reviewed literature. Some — like tesamorelin — have subsequently achieved FDA approval.

The Development Pipeline

Preclinical research begins with cell studies (in vitro) and animal models (in vivo). This stage establishes basic safety, mechanism, and a dose range. The vast majority of compounds never advance past this stage.

Phase I trials are first-in-human studies, typically in 20–80 healthy volunteers. The primary goal is safety and pharmacokinetics — how the compound is absorbed, distributed, metabolised, and excreted. Thymosin Beta-4 (TB-500) has Phase I data in 84 subjects establishing it as safe and well-tolerated in humans.

Phase II trials test efficacy for the first time in a target population — typically 100–500 subjects. The retatrutide Phase 2 trial (338 subjects, NEJM 2023) is an example of a Phase II demonstrating remarkable efficacy.

Phase III trials are large, multi-centre, pivotal studies — typically 1,000–5,000 subjects — designed to confirm efficacy and long-term safety to the standard required for regulatory approval. Semaglutide's STEP-1 (1,961 subjects) and tirzepatide's SURMOUNT-1 (2,539 subjects) are Phase III trials.

Regulatory approval is the final stage. Once approved, a compound is no longer a "research peptide" for its approved indication — but may remain a research peptide for other applications being studied.

Why This Matters

Understanding where a peptide sits in the pipeline tells you how much human evidence exists. A compound with robust Phase III data in thousands of subjects is qualitatively different from one with only animal studies. At Lotus Labs, all products are supplied for research purposes — we publish the underlying clinical evidence so researchers understand the strength of the available data for each compound.